trial · primary record
Selumetinib
Neurofibromatosis Type 2
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2028-12-31 |
| Primary endpoint | Objective Response Rate (ORR)in NF2-related vestibular schwannoma assessed according to the REiNS criteria |
| Registry ID | NCT07707947 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:51.088Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07707947
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- SELUMETINIB · approval
- Selumetinib · compound